Drew Johnson, a candidate for Nevada State Treasurer, expressed concerns about adopting a Most Favored-Nation (MFN) drug pricing model. He said that such a policy would negatively impact Americans and urged international partners to increase their contributions to pharmaceutical innovation. Johnson made these remarks on the social media platform X.
“A Most Favored-Nation drug pricing scheme would be devastating for American patients, jobs, and innovation,” said Johnson, Congress Nominee. “The answer isn’t importing Europe’s price controls — it’s making Europe pay its fair share for innovation without punishing Americans in the process.”
Most Favored-Nation drug pricing policies propose aligning U.S. prescription drug prices with those in other developed countries. These policies have received mixed reactions from policymakers and advocacy groups. According to the Wall Street Journal, some support MFN as a means to reduce costs, while others warn it could pose risks to innovation and supply.
A 2023 report by the RAND Corporation highlights that U.S. prescription drug prices are, on average, 2.5 times higher than those in 32 countries within the Organisation for Economic Co-operation and Development (OECD). MFN proposals aim to address this disparity by referencing European and other international pricing models.
The Congressional Budget Office conducted a study indicating that MFN drug pricing proposals might reduce U.S. pharmaceutical revenues by up to $75 billion over ten years. While this could potentially lower drug costs, it may also affect jobs and slow the rate of new drug development.
Johnson is recognized as a policy analyst and columnist advocating for free-market healthcare reforms. The Washington Times describes him as having extensive experience in writing about drug pricing policy and government transparency.
